(b)(4).The ziv6-35-125-7.0-40-ptx stent of lot number c772911 was implanted in the patient and is therefore unavailable for evaluation.With the information provided a document based investigation was carried out.The patient had the following pre-existing conditions: hypertension, hypercholesterolemia, smoker.It was stated in the complaint by the originator that no further information will be provided and images are unavailable.There is no evidence to suggest that this event did not occur, therefore the complaint is confirmed based on customer testimony.Restenosis is a common adverse event of endovascular procedures and can be caused by injury to the vessel (e.G.During percutaneous transluminal angioplasty (pta) and/or stenting).Vessel injury provokes an inflammatory response that leads to (or amplifies) the restenosis process.It may be noted that surface of the zilver ptx stent is coated with the drug (paclitaxel) to help prevent subsequent restenosis of the artery.It can be therefore stated that it is very unlikely that the reported restenosis could have occurred due to zilver ptx malfunction; however as no imaging was available at the time of investigation, a definitive root cause of this event cannot be determined at this time.In addition worsened claudication was also observed on the patient.It can be noted that this symptom indicates progression of peripheral artery disease and can also be associated with the restenosis process.It may be noted that the packaging insert lists restenosis of the stented artery as a known potential adverse event associated with placement of this device.Worsened claudication is also listed as a potential adverse event in the packaging insert following the placement of this device.Prior to distribution all zilver ptx devices are subject to visual inspection and functional checks to ensure device integrity.A review of the relevant manufacturing records revealed no discrepancies that could have contributed to this complaint.Upon review of complaints, this failure mode has not occurred previously with the lot number c772911.Based on the information available to date, there is no evidence to suggest that there are any manufacturing issues associated with the lot number c772911.Pta was performed against this issue and the patient's condition was improved.Complaints of this nature will continue to be monitored for any potential emerging trends.
|
(b)(6) 2012 - there were two isolated target lesions in the sfa of the patient.One was in the upper part and one was in the lower part of the sfa.A ziv6-35-125-7.0-40-ptx (lot#c772911) was placed in upper part of the left sfa.Also, two ziv6-35-125-7.0-120-ptx (lot#c776080) were placed in the lower part of the sfa.The stent placed in the upper part and the stents placed in the lower part were not overlapped since the lesions were away each other.(b)(6) 2016 - 100% restenosis in the left upper sfa, where one 7-40 stent was placed, was confirmed.Worsened intermittnt claudication and worsened rutherford were observed on the patient.(b)(6) 2016 - pta was performed against this issue and the patient's condition was improved.
|